6. Guardant Health Inc. (NASDAQ:GH)
Number of Hedge Fund Holders — 80
Liquid Biopsy Gains a Broader Role in Cancer Treatment Decisions
Guardant Health, Inc. (NASDAQ: GH) is expanding its precision oncology business as blood-based testing becomes increasingly relevant to treatment selection and monitoring. On September 4, the FDA approved Guardant360 CDx as a companion diagnostic for camizestrant in a defined advanced breast cancer setting. The associated drug indication involves detecting an ESR1 mutation during treatment with an aromatase inhibitor and a CDK4/6 inhibitor. This development broadens the opportunity for molecular testing during ongoing care, rather than only at diagnosis. The distinction matters commercially because testing may become relevant as disease biology changes and physicians consider whether treatment should change with it.
The financial results show momentum across several parts of the business. Second-quarter revenue rose 44% to approximately $335 million, with oncology revenue increasing 38% to $219.1 million. Oncology testing volume grew 63% to roughly 104,000 tests. Screening added another source of expansion, generating $52.9 million in revenue as Shield test volume reached approximately 66,000, compared with about 16,000 a year earlier. Co-Chief Executive Officer Helmy Eltoukhy said growth was supported by “acceleration across every product.” Management raised its full-year revenue guidance to $1.34 billion–$1.36 billion, reflecting expected growth of 36%–38%.
For investors evaluating liquid biopsy stocks, the attraction is a business with several potential sources of demand: therapy selection, disease monitoring, screening, and services for pharmaceutical research. Each has different reimbursement and profitability considerations, making the quality of growth as important as the headline percentage. The companion diagnostic identifies patients eligible for a treatment; the drug’s clinical outcomes should not be credited to the test alone. Longer term, the investment case depends on converting clinical relevance into reimbursed volume while controlling laboratory, development, and commercial costs. A larger testing footprint creates opportunity, but sustainable margins must eventually do some of the talking.
Ranking rationale — Guardant Health, Inc. (NASDAQ: GH) ranks sixth with 80 hedge fund holders. Its breast cancer diagnostic expansion, oncology testing growth, and screening momentum support inclusion, while reimbursement, spending, and the conversion of revenue growth into durable profitability remain decisive.
YOU MUST READ THIS: 10 Promising Small-Cap Biotech Stocks to Watch and 10 Best Biotech Stocks Under $10 to Buy Now.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
